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Table I
Dosing parameters and gene-therapy outcomes1
Subject Age (years)
gender
Genotype LentiGlobin transduced CD34+
cells
Day of ANC
engraftment
bAT87Q-Hb/Total
Hb (g/dL)
(day of test)
Last PRBC
transfusion
VCN Dose (x106 per kg)
205-1201 19, F b0/bE 1.5 8.9 day +13 7.2/10.2 (day+180 ) Day+10
205-1202 16, M b0/bE 2.1 13.6 day +15 6.8/11.0 (day+135) Day+15
204-1102 18, F b0/bE 1.0/1.12 6.5 day +17 1.7/8.6 (day + 90) Day+14 and+96
1Data as of 31 July 2014; 2more than one drug product were manufactured.
Data being presented on behalf of all HGB-204 and 205 Study Investigators.
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tients with b-thalassemia major. Transplantation with
autologous CD34+ cells transduced with a replication-
defective, self-inactivating lentiviral vector (LentiGlobin
BB305) containing an engineered b-globin gene (bAT87Q)
resulted in early reduction or elimination of transfusion re-
quirements in the ﬁrst 3 subjects treated in the ongoing
HGB-204 and 205 studies. Herein, we provide additional
follow-up data on the three subjects.
Subjects and Methods: Transfusion-dependent subjects
with b-thalassemia major undergo HSC collection via mobi-
lized peripheral blood apheresis and CD34+ cells are selected.
Estimation of the mean ex-vivo vector copy number (VCN) is
obtained by quantitative PCR performed on pooled colony-
forming progenitors. Subjects undergo myeloablation
with intravenous busulfan (Bu), followed by infusion of
transduced CD34+ cells. Subjects are monitored for hema-
tologic engraftment, bAT87Q-globin expression (by high
performance liquid chromatography) and transfusion re-
quirements. Integration site analysis (ISA, by linear ampliﬁ-
cation-mediated PCR and high-throughput sequencing on
nucleated cells) and replication-competent lentivirus (RCL)
assays are performed for safety monitoring.
Results: 3 subjects (b0/bE) have undergone gene therapy via
infusion of transduced CD34+ cells. Outcomes data are
shown in Table I. All adverse events to date were related to
Bu conditioning, without any serious or gene therapy-
related adverse events. All three subjects are producing
bAT87Q-globin and the ﬁrst two subjects remain transfusion
independent after a median follow-up of 150 days (range:
127-246 days). Details of patient eligibility, vector design,
interpretation of post-transplant VCN, and details of safety
monitoring (ISA and RCL analysis) for gene therapy of
thalassemia will be discussed. Major differences between
BMT and gene therapy for thalassemia will be highlighted.
Conclusion: Ex-vivo gene transfer of bAT87Q-globin to autol-
ogous HSCs has resulted in clinically beneﬁcial production of
b-globin and may be a promising approach for the treatment
of patients with b-thalassemia major.6
Haploidentical BMT Using Fully Myeloablative
Conditioning, T Cell Replete Bone Marrow Grafts, and
Post-Transplant Cyclophosphamide (PT/Cy) Has Limited
Toxicity and Promising Efﬁcacy in Largest Reported
Experience with High Risk Hematologic Malignancies
Heather J. Symons 1, Allen Chen 2, Christopher Gamper 2,
Kenneth R. Cooke 3, Margaret Showel 4, Javier Bolaños-Meade 5,
Leo Luznik 1, Richard J. Jones 6, Ephraim J. Fuchs 1. 1 Department
of Oncology, The Johns Hopkins University School of Medicine,
Baltimore, MD; 2 Pediatric Oncology, Johns Hopkins Hospital,
Baltimore, MD; 3 Pediatric Bone Marrow Transplant, Sidney
Kimmel Cancer Center, Johns Hopkins University, Baltimore,
MD; 4Oncology, Johns Hopkins University, Baltimore, MD;5 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
University, Baltimore, MD; 6Department of Oncology, The Johns
Hopkins University, Baltimore, MD
Promising results have been reported for patients with
high-risk hematologic malignancies undergoing T-cell-
replete myeloablative hematopoietic stem cell trans-
plantation (HSCT) from HLA-haploidentical donors with
post-transplantation cyclophosphamide (PT/Cy). Here, we
report the largest patient experience (n¼97) for leukemias in
complete remission (CR) and chemosensitive lymphomas
with at least a partial remission (PR) enrolled on, or treated
according to, our now completed single-institution phase II
clinical trial. Conditioning consisted of IV Busulfan (phar-
macokinetically adjusted) days e6 to e3 and Cy (50 mg/kg/
day) days e2 and e1 except for patients with acute lym-
phocytic leukemia or lymphoblastic lymphoma who
received Cy (50 mg/kg/day) days e5 and e4 and total body
irradiation (200 cGy twice daily) days e3 to -1. T-cell-replete
bone marrow from haploidentical related donors was used
for all patients. Postgrafting immunosuppression consisted
of Cy (50 mg/kg/day) days 3 and 4, followed by mycophe-
nolate mofetil for 30 days and tacrolimus for 6 months.
Ninety-seven patients with a median age of 42y (range, 1-65)
were treated. Diagnoses included AML (CR1¼24, CR>2¼10,
any CR with minimal residual disease¼11), ALL (CR1¼9,
CR>2¼4, any CR with minimal residual disease¼6), mixed
lineage leukemia (2), MDS (13), CML (chronic phase 2¼2),
CMML (1), CLL (1), granulocytic sarcoma (2), multiple
myeloma (1), lymphoma in chemosensitive PR (5), and
lymphoma in CR (6). Donor engraftment occurred in 73/82
(89%) patients evaluable at Day 60. Median time to neutro-
phils >500/mL was 23 days and platelets >20,000/mL was 27
days. Cumulative incidences of acute GVHD grades II-IV and
grades III-IV at day 100 were 17% and 7%, respectively, and
chronic GVHD at 6 months was 16%. Transplant-related
mortality (TRM) at 100 days was 11%. The cumulative inci-
dence of relapse at 3y was 44%. For leukemia patients in CR
with no detectable MRD the cumulative incidence of relapse
at 2y was 33% in CR1 and 27% in >CR2. For leukemia patients
in any CR with detectable MRD by ﬂow cytometry and/or
cytogenetics and/or FISH, the cumulative incidence of
relapse at 2 years is 70%. Among lymphoma patients, the
cumulative incidence of relapse at 2y for those in CR is 33%
and in PR 25%.With a median follow-up of surviving patients
of 474 days (range, 60-1782), actuarial overall survival is 72%
at 1y and 57% at 2y. With a median follow-up of event-free
patients of 444 days (60-1782), actuarial event-free survival
is 55% at 1y and 49% at 2y. For the largest reported patient
population undergoing myeloablative HLA-haploidentical
HSCT for high-risk hematologic malignancies with T-cell
replete bone marrow and PT/Cy, we have demonstrated
acceptable rates of engraftment, GVHD, relapse, survival, and
TRM, similar to HLA-matched HSCT. This approach is there-
fore a feasible option for high risk patients who lack timely
access to an HLA-matched donor.
